ProfileGDS5678 / 1434423_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 79% 75% 83% 81% 81% 69% 76% 79% 83% 84% 82% 84% 81% 83% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.4813679
GSM967853U87-EV human glioblastoma xenograft - Control 24.953575
GSM967854U87-EV human glioblastoma xenograft - Control 36.140683
GSM967855U87-EV human glioblastoma xenograft - Control 45.9919281
GSM967856U87-EV human glioblastoma xenograft - Control 55.8503381
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.2913269
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.0165276
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.5397979
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.0716183
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.2307684
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.8710482
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.2529984
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.8165681
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.0380983